tetano
Editor, Senior Moderator
Inflamm Bowel Dis
. 2022 Jul 13;izac138.
doi: 10.1093/ibd/izac138. Online ahead of print.
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Kimberly N Weaver[SUP] 1 [/SUP], Xian Zhang[SUP] 2 [/SUP], Xiangfeng Dai[SUP] 3 [/SUP], Wenli Chen[SUP] 3 [/SUP], Runa Watkins[SUP] 4 [/SUP], Jeremy Adler[SUP] 5 [/SUP], Marla C Dubinsky[SUP] 6 [/SUP], Arthur Kastl[SUP] 7 [/SUP], Athos Bousvaros[SUP] 8 [/SUP], Jennifer A Strople[SUP] 9 [/SUP], Raymond K Cross[SUP] 10 [/SUP], Peter D R Higgins[SUP] 11 [/SUP], Ryan C Ungaro[SUP] 12 [/SUP], Meenakshi Bewtra[SUP] 13 [/SUP], Emanuelle Bellaguarda[SUP] 14 [/SUP], Francis A Farraye[SUP] 15 [/SUP], Riley Craig[SUP] 2 [/SUP], Cristian Hernandez[SUP] 2 [/SUP], Margie E Boccieri[SUP] 2 [/SUP], Ann Firestine[SUP] 2 [/SUP], Kelly Y Chun[SUP] 16 [/SUP], Millie D Long[SUP] 1 3 [/SUP], Michael D Kappelman[SUP] 2 3 [/SUP]
Affiliations
No abstract available
Plain language summary
We demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.
. 2022 Jul 13;izac138.
doi: 10.1093/ibd/izac138. Online ahead of print.
Low Rates of Breakthrough COVID-19 Infection After SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease
Kimberly N Weaver[SUP] 1 [/SUP], Xian Zhang[SUP] 2 [/SUP], Xiangfeng Dai[SUP] 3 [/SUP], Wenli Chen[SUP] 3 [/SUP], Runa Watkins[SUP] 4 [/SUP], Jeremy Adler[SUP] 5 [/SUP], Marla C Dubinsky[SUP] 6 [/SUP], Arthur Kastl[SUP] 7 [/SUP], Athos Bousvaros[SUP] 8 [/SUP], Jennifer A Strople[SUP] 9 [/SUP], Raymond K Cross[SUP] 10 [/SUP], Peter D R Higgins[SUP] 11 [/SUP], Ryan C Ungaro[SUP] 12 [/SUP], Meenakshi Bewtra[SUP] 13 [/SUP], Emanuelle Bellaguarda[SUP] 14 [/SUP], Francis A Farraye[SUP] 15 [/SUP], Riley Craig[SUP] 2 [/SUP], Cristian Hernandez[SUP] 2 [/SUP], Margie E Boccieri[SUP] 2 [/SUP], Ann Firestine[SUP] 2 [/SUP], Kelly Y Chun[SUP] 16 [/SUP], Millie D Long[SUP] 1 3 [/SUP], Michael D Kappelman[SUP] 2 3 [/SUP]
Affiliations
- PMID: 35830416
- DOI: 10.1093/ibd/izac138
No abstract available
Plain language summary
We demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.